Mirvetuximab soravtansine: FRα-targeting ADC Treatment of epithelial ovarian cancer

Drugs of the Future

Volumn 41, Issue 9, 2016, Pages 539-545

  Gunderson, C C ^a   Moore, K N ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Antibody drug conjugate; Female reproductive system cancer therapy; Folate receptor alpha; IMGN 853; Mirvetuximab soravtansine; Oncolytic drugs; Ovarian cancer therapy

Indexed keywords

FOLATE RECEPTOR 1; MIRVETUXIMAB SORAVTANSINE; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL STUDY; DRUG METABOLISM; DRUG SAFETY; OVARY CARCINOMA; PRECLINICAL STUDY; PROTEIN EXPRESSION;

EID: 84995543292     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2016.041.09.2544475     Document Type: Article

References (34)

1. American Cancer Society Cancer Facts & Figures. 2016.
2. Davis, A., Tinker, A.V., Friedlander, M. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 2014, 133(3): 624-31.
3. Bookman, M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999, 4(2): 87-94.
4. Markman, M., Rothman, R., Hakes, T. et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9(3): 389-93.
5. Gore, M.E., Fryatt, I., Wiltshaw, E., Dawson, T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990, 36(2): 207-11.
6. Rose, P.G., Fusco, N., Fluellen, L., Rodriguez, M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998, 16(4): 1494-7.
7. Ferrandina, G., Ludovisi, M., Lorusso, D. et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008, 26(6): 890-6.
8. Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., Lacave, A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19(14): 3312-22.
9. Elnakat, H., Ratnam, M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56(8): 1067-84.
10. Salazar, M.D., Ratnam, M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 2007, 26(1): 141-52.
11. Ledermann, J.A., Canevari, S., Thigpen, T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 2015, 26(10): 2034-43.
12. Kalli, K.R., Oberg, A.L., Keeney, G.L., Christianson, T.J., Low, P.S., Knutson, K.L., Hartmann, L.C. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008, 108(3): 619-26.
13. Toffoli, G., Russo, A., Gallo, A. et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998, 79(2): 121-6.
14. Marchetti, C., Palaia, I., Giorgini, M. et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther 2014, 7: 1223-36.
15. Vergote, I.B., Marth, C., Coleman, R.L. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 2015, 34(1): 41-52.
16. Thomas, A., Teicher, B.A., Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016, 17(6): e254-62.
17. Lambert, J.M. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013, 76(2): 248-62.
18. Lutz, R.J. Targeting the folate receptor for the treatment of ovarian cancer. Transl Cancer Res 2015, 4: 118-26.
19. Erickson, H.K., Widdison, W.C., Mayo, M.F., Whiteman, K., Audette, C., Wilhelm, S.D., Singh, R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010, 21(1): 84-92.
20. Hong, E.E., Erickson, H., Lutz, R.J. et al. Design of coltuximab ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation. Mol Pharm 2015, 12(6): 1703-16.
21. Ab, O., Whiteman, K.R., Bartle, L.M. et al. IMGN853, a folate receptoralpha (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther 2015, 14(7): 1605-13.
22. Erickson, H.K., Park, P.U., Widdison, W.C. et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006, 66(8): 4426-33.
23. Kovtun, Y.V., Audette, C.A., Ye, Y. et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006, 66(6): 3214-21.
24. Drewinko, B., Patchen, M., Yang, L.Y., Barlogie, B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 1981, 41(6): 2328-33.
25. Ponte, J.F., Coccia, J., Lanieri, L., Gabriel, R., Pinkas, J., Ruiz-Soto, R. Preclinical evaluation of mirvetuximab soravtansine (IMGN853) combination therapy in ovarian cancer xenograft models. Mol Cancer Ther [27th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (November 5-9, Boston) 2015] 2015, 14(12, Suppl. 2): Abst C170.
26. Moore, K.N., Martin, L.P., Matulonis, U.A. et al. IMGN (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts). J Clin Oncol [52nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2016] 2016, 34(Suppl.): Abst 5567.
27. Moore, K.N., Ponte, J., LoRusso, P. et al. Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors. J Clin Oncol [50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014] 2014, 32(5s): Abst 5571.
28. Kurkjian, C., LoRusso, P., Sankhala, K.K. et al. A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors. J Clin Oncol [49th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013] 2013, 31(Suppl.): Abst 2573.
29. Eaton, J.S., Miller, P.E., Mannis, M.J., Murphy, C.J. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 2015, 31(10): 589-604.
30. Moore, K.N., Martin, L.P., Seward, S.M. et al. Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): phase I trial. J Clin Oncol [51st Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Chicago) 2015] 2015, 33(Suppl.): Abst 5518.
31. Pujade-Lauraine, E., Hilpert, F., Weber, B. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32(13): 1302-8.
32. Hanker, L.C., Loibl, S., Burchardi, N. et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/ platinum-based therapy. Ann Oncol 2012, 23(10): 2605-12.
33. Raufi, A., Ebrahim, A.S., Al-Katib, A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res 2013, 5: 225-33.
34. Tang, R., Cohen, S., Perrot, J.Y. et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009, 9: 199.